SGMT
Sagimet Biosciences Inc.·Healthcare
5.30
6.028%(−0.34)
Market ClosedLast Updated: — ET
52W L: $2.0252W H: $11.41
SGMT NEWS
globenewswire.com
5d ago
Sagimet Biosciences Announces Poster and Oral Presentations at the Fueling MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN MATEO, Calif., April 06, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that a poster presentation and an oral presentation featuring analysis from the Phase 2b FASCINATE 2 trial of denifanstat in MASH will be delivered at the Fueling MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium being held April 12-15, 2026 in Vancouver, BC, Canada.
globenewswire.com
Mar 11
Sagimet Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates
Completed Phase 1 pharmacokinetic (PK) clinical trial of denifanstat and resmetirom combination Phase 2 trial of denifanstat/resmetirom combination in F4 MASH patients planned to initiate in 2H 2026 Secured global, exclusive license to TAPI's innovative forms of resmetirom active pharmaceutical ingredients (API) First-in-human Phase 1 clinical trial of FASN inhibitor TVB-3567 ongoing Positive topline results in open-label Phase 3 trial evaluating the long-term safety of denifanstat in patients with moderate to severe acne in China reported by Ascletis China's National Medical Products Administration (NMPA) accepted Ascletis' New Drug Application (NDA) for denifanstat for the treatment of moderate to severe acne SAN MATEO, Calif., March 11, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided recent corporate updates.
seekingalpha.com
Mar 3
Sagimet Biosciences Inc. (SGMT) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript
Sagimet Biosciences Inc. (SGMT) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript
defenseworld.net
Mar 3
Sagimet Biosciences Highlights Denifanstat MASH Data, Combo Plans at Oppenheimer Healthcare Conf.
Sagimet Biosciences (NASDAQ: SGMT) used an investor discussion at Oppenheimer's 36th Annual Healthcare Life Sciences Conference to outline its strategy around fatty acid synthase (FASN) inhibition, with development efforts centered on metabolic dysfunction-associated steatohepatitis (MASH), acne, and select solid tumors. Company executives emphasized that its lead candidate, denifanstat, is designed to address disease biology associated with
globenewswire.com
Feb 25
Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences
SAN MATEO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will participate in three upcoming investor conferences.
defenseworld.net
Feb 17
Sagimet Biosciences (NASDAQ:SGMT) vs. AC Immune (NASDAQ:ACIU) Financial Survey
AC Immune (NASDAQ: ACIU - Get Free Report) and Sagimet Biosciences (NASDAQ: SGMT - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, dividends and risk. Analyst Ratings This is a breakdown of
